Qinghai Biotech Pharmaceutical Group Limited, an investment holding company, engages in the health care and dental business in the People's Republic of China and internationally. It produces and sells dental prosthetics, including crowns and bridges, removable full and partial dentures, implants, and full-cast restorations, as well as provides sport rehabilitation services comprising postoperative rehabilitation, sports injury rehabilitation, chronic pain, scoliosis, deformity correction, and other rehabilitation services; and health leisure services. The company is also involved in the investment holding of loan receivable; provision of medical consultation and other medical services; and trading and provision of medical technology development. In addition, it trades in dental prosthetics, implant instruments, and other dental products. The company was formerly known as Kaisa Health Group Holdings Limited and changed its name to Qinghai Biotech Pharmaceutical Group Limited in September 2026. Qinghai Biotech Pharmaceutical Group Limited was founded in 1971 and is headquartered in Central, Hong Kong.
Research context
Kaisa Health Group Holdings Limited appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Kaisa Health Group Holdings Limited is currently in a long term uptrend where the price is trading 0.7% above its 200 day moving average.
From a valuation standpoint, the stock is 96.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Kaisa Health Group Holdings Limited's total revenue sank by 18.9% to $108M since the same quarter in the previous year.
Its net income has increased by 90.7% to $-34M since the same quarter in the previous year.
Finally, its free cash flow fell by 147.2% to $-21M since the same quarter in the previous year.
Based on the above factors, Kaisa Health Group Holdings Limited gets an overall score of 3/5.